• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺苷激酶同工型的基因表达与结直肠癌中CD39和CD73外切核苷酸酶表达之间的关系

Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer.

作者信息

Zhulai G A, Shibaev M I

机构信息

Institute of Biology, Karelian Research Centre, Russian Academy of Sciences, Petrozavodsk, 185910 Russian Federation.

Endoscopic Department, Baranov Republican Hospital, Petrozavodsk, 185910 Russian Federation.

出版信息

Acta Naturae. 2023 Apr-Jun;15(2):42-49. doi: 10.32607/actanaturae.11871.

DOI:10.32607/actanaturae.11871
PMID:37538807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10395772/
Abstract

Tumor cells have the capacity to create an adenosine-rich immunosuppressive environment, which can interfere with antitumor immunotherapy. Approaches are currently being developed with a view to suppressing the production of adenosine or its signals. Such approaches include the use of antibodies to inhibit CD39, CD73, and adenosine-receptor antagonists. However, the abundance of enzymatic pathways that control the ATP-adenosine balance, as well as the still poorly understood intracellular adenosine regulation, makes the hoped-for success unlikely. In the present study, the enzyme adenosine kinase (ADK) needed to convert adenosine to adenosine monophosphate, thereby regulating its levels, was investigated. To do so, peripheral blood samples from patients with colorectal cancer (CRC) ( = 31) were collected with blood samples from healthy donors ( = 17) used as controls. ADK gene expression levels and those of its long () and short () isoforms were measured. The relationship between the levels of gene expression and that of , , and genes was analyzed. It turned out that in the group of CRC patients (stages III-IV), the level of mRNA was lower ( < 0.0011) when compared to that of the control. For the first time, an average correlation was found between the level of expression of and ( = -0.468 at = 0.043) and between and ( = 0.518 at = 0.0232) in CRC patients. Flow cytometry was used to assess the content of CD39/CD73-expressing CD8, CD4 and Treg lymphocytes, as well as their relationship with the level of ADK gene expression in CRC patients. But no significant correlations were found.

摘要

肿瘤细胞有能力营造一个富含腺苷的免疫抑制环境,这会干扰抗肿瘤免疫疗法。目前正在研发相关方法以抑制腺苷的产生或其信号传导。此类方法包括使用抗体抑制CD39、CD73以及腺苷受体拮抗剂。然而,控制ATP - 腺苷平衡的酶促途径众多,且细胞内腺苷调节仍知之甚少,这使得预期的成功不太可能实现。在本研究中,对将腺苷转化为单磷酸腺苷从而调节其水平所需的腺苷激酶(ADK)进行了研究。为此,收集了31例结直肠癌(CRC)患者的外周血样本,并以17例健康供者的血样作为对照。测量了ADK基因表达水平及其长()和短()异构体的表达水平。分析了基因表达水平与、和基因表达水平之间的关系。结果发现,在CRC患者(III - IV期)组中,与对照组相比,mRNA水平较低(<0.0011)。首次在CRC患者中发现与的表达水平之间存在平均相关性(在= 0.043时,= -0.468)以及与之间存在平均相关性(在= 0.0232时,= 0.518)。使用流式细胞术评估CRC患者中表达CD39/CD73的CD8、CD4和调节性T淋巴细胞的含量,以及它们与ADK基因表达水平的关系。但未发现显著相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/058f79e753f8/AN20758251-15-02-042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/acfddba460ea/AN20758251-15-02-042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/6d110cfb58b6/AN20758251-15-02-042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/058f79e753f8/AN20758251-15-02-042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/acfddba460ea/AN20758251-15-02-042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/6d110cfb58b6/AN20758251-15-02-042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4efd/10395772/058f79e753f8/AN20758251-15-02-042-g003.jpg

相似文献

1
Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer.腺苷激酶同工型的基因表达与结直肠癌中CD39和CD73外切核苷酸酶表达之间的关系
Acta Naturae. 2023 Apr-Jun;15(2):42-49. doi: 10.32607/actanaturae.11871.
2
Expression of ADK-S and ADK-L Isoforms and Their Association with CD39/CD73/A2aR in Colorectal Cancer.ADK-S 和 ADK-L 同工型的表达及其与结直肠癌中 CD39/CD73/A2aR 的关联。
Bull Exp Biol Med. 2023 Nov;176(1):91-95. doi: 10.1007/s10517-023-05973-1. Epub 2023 Dec 12.
3
The abnormal function of CD39 regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia.大剂量地塞米松可纠正原发免疫性血小板减少症患者调节性 T 细胞的异常功能。
Ann Hematol. 2019 Aug;98(8):1845-1854. doi: 10.1007/s00277-019-03716-9. Epub 2019 Jun 1.
4
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.人 CD4+ CD39+ 调节性 T 细胞在共表达表面 CD73 或与 CD73+ 外泌体或 CD73+ 细胞接触时会产生腺苷。
Clin Exp Immunol. 2014 Aug;177(2):531-43. doi: 10.1111/cei.12354.
5
Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.癌中的腺苷代谢酶、腺苷激酶和腺苷脱氨酶。
Biomolecules. 2022 Mar 8;12(3):418. doi: 10.3390/biom12030418.
6
Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4 CD25 Foxp3 regulatory T-cells in psoriasis.银屑病中CD4 CD25 Foxp3调节性T细胞中外切酶CD39/CD73和腺苷受体2A的表型分析。
Australas J Dermatol. 2018 Feb;59(1):e31-e38. doi: 10.1111/ajd.12561. Epub 2017 Mar 15.
7
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.在多发性骨髓瘤中,通过 CD39 和 CD73 将 ATP 转化为腺苷,可以与腺苷受体 A2A 阻断一起成功靶向。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000610.
8
Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.非小细胞肺癌中核苷酸酶 CD73 和 CD39 的表达与缺氧和免疫抑制途径有关。
Life Sci. 2020 Oct 15;259:118389. doi: 10.1016/j.lfs.2020.118389. Epub 2020 Sep 6.
9
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.抑制肿瘤细胞表面的 CD39 酶活性可减轻其免疫抑制活性。
Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.
10
CD39/CD73/A2AR pathway and cancer immunotherapy.CD39/CD73/A2AR 通路与癌症免疫治疗。
Mol Cancer. 2023 Mar 2;22(1):44. doi: 10.1186/s12943-023-01733-x.

本文引用的文献

1
Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Therapy.脱氧核糖核酸甲基化中的腺苷激酶:治疗中不依赖腺苷受体的途径
Front Pharmacol. 2022 Jun 1;13:908882. doi: 10.3389/fphar.2022.908882. eCollection 2022.
2
Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.癌中的腺苷代谢酶、腺苷激酶和腺苷脱氨酶。
Biomolecules. 2022 Mar 8;12(3):418. doi: 10.3390/biom12030418.
3
Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.癌症中通过CD39和CD73对免疫反应的调节:新型检查点。
Life Sci. 2021 Oct 1;282:119826. doi: 10.1016/j.lfs.2021.119826. Epub 2021 Jul 12.
4
Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines.腺苷激酶表达决定癌细胞系中的DNA甲基化。
ACS Pharmacol Transl Sci. 2021 Feb 16;4(2):680-686. doi: 10.1021/acsptsci.1c00008. eCollection 2021 Apr 9.
5
Targeting adenosine and regulatory T cells in cancer immunotherapy.在癌症免疫治疗中靶向腺苷和调节性 T 细胞。
Hum Immunol. 2021 Apr;82(4):270-278. doi: 10.1016/j.humimm.2020.12.005. Epub 2021 Feb 18.
6
Targeting the A2AR in cancer; early lessons from the clinic.靶向肿瘤中的 A2AR:来自临床的早期经验。
Curr Opin Pharmacol. 2020 Aug;53:126-133. doi: 10.1016/j.coph.2020.08.003. Epub 2020 Sep 29.
7
Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.抑制腺苷通路增强癌症免疫疗法:联合治疗的潜力。
Annu Rev Med. 2021 Jan 27;72:331-348. doi: 10.1146/annurev-med-060619-023155. Epub 2020 Sep 9.
8
Adenosine and adenosine receptors in colorectal cancer.结直肠癌中的腺苷及腺苷受体
Int Immunopharmacol. 2020 Oct;87:106853. doi: 10.1016/j.intimp.2020.106853. Epub 2020 Aug 2.
9
Dysregulation of adenosine kinase isoforms in breast cancer.乳腺癌中腺苷激酶同工型的失调
Oncotarget. 2019 Dec 31;10(68):7238-7250. doi: 10.18632/oncotarget.27364.
10
Adenosine Metabolism: Emerging Concepts for Cancer Therapy.腺苷代谢:癌症治疗的新兴概念。
Cancer Cell. 2019 Dec 9;36(6):582-596. doi: 10.1016/j.ccell.2019.10.007.